Pharma & Healthcare

Global Polypeptide Vaccine Market Research Report 2026

This report delivers a comprehensive overview of the global Polypeptide Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Polypeptide Vaccine. The Polypeptide Vaccine market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Polypeptide Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Polypeptide Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AmbioPharm
Almac
ACT
Ultimovacs
Marker Therapeutics, Inc.
Immatics
OncoPep
Anergis
Sellas Life Sciences
Segment by Type
Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Others
by Application
Infectious Disease Prevention
Cancer Immunotherapy
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Polypeptide Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Polypeptide Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Polypeptide Vaccine Market Overview
1.1 Product Definition
1.2 Polypeptide Vaccine by Type
1.2.1 Global Polypeptide Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Synthetic Polypeptide Vaccines
1.2.3 Recombinant Polypeptide Vaccine
1.2.4 Others
1.3 Polypeptide Vaccine by Application
1.3.1 Global Polypeptide Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Infectious Disease Prevention
1.3.3 Cancer Immunotherapy
1.3.4 Others
1.4 Global Polypeptide Vaccine Market Size Estimates and Forecasts
1.4.1 Global Polypeptide Vaccine Revenue 2021–2032
1.4.2 Global Polypeptide Vaccine Sales 2021–2032
1.4.3 Global Polypeptide Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Polypeptide Vaccine Market Competition by Manufacturers
2.1 Global Polypeptide Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Polypeptide Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Polypeptide Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Polypeptide Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Polypeptide Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Polypeptide Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Polypeptide Vaccine, Date of Entry into the Industry
2.8 Global Polypeptide Vaccine Market Competitive Situation and Trends
2.8.1 Global Polypeptide Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Polypeptide Vaccine Players Market Share by Revenue
2.8.3 Global Polypeptide Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Polypeptide Vaccine Market Scenario by Region
3.1 Global Polypeptide Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Polypeptide Vaccine Sales by Region: 2021–2032
3.2.1 Global Polypeptide Vaccine Sales by Region: 2021–2026
3.2.2 Global Polypeptide Vaccine Sales by Region: 2027–2032
3.3 Global Polypeptide Vaccine Revenue by Region: 2021–2032
3.3.1 Global Polypeptide Vaccine Revenue by Region: 2021–2026
3.3.2 Global Polypeptide Vaccine Revenue by Region: 2027–2032
3.4 North America Polypeptide Vaccine Market Facts & Figures by Country
3.4.1 North America Polypeptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Polypeptide Vaccine Sales by Country (2021–2032)
3.4.3 North America Polypeptide Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Polypeptide Vaccine Market Facts & Figures by Country
3.5.1 Europe Polypeptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Polypeptide Vaccine Sales by Country (2021–2032)
3.5.3 Europe Polypeptide Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Polypeptide Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Polypeptide Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Polypeptide Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Polypeptide Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Polypeptide Vaccine Market Facts & Figures by Country
3.7.1 Latin America Polypeptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Polypeptide Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Polypeptide Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Polypeptide Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Polypeptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Polypeptide Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Polypeptide Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Polypeptide Vaccine Sales by Type (2021–2032)
4.1.1 Global Polypeptide Vaccine Sales by Type (2021–2026)
4.1.2 Global Polypeptide Vaccine Sales by Type (2027–2032)
4.1.3 Global Polypeptide Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Polypeptide Vaccine Revenue by Type (2021–2032)
4.2.1 Global Polypeptide Vaccine Revenue by Type (2021–2026)
4.2.2 Global Polypeptide Vaccine Revenue by Type (2027–2032)
4.2.3 Global Polypeptide Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Polypeptide Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Polypeptide Vaccine Sales by Application (2021–2032)
5.1.1 Global Polypeptide Vaccine Sales by Application (2021–2026)
5.1.2 Global Polypeptide Vaccine Sales by Application (2027–2032)
5.1.3 Global Polypeptide Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Polypeptide Vaccine Revenue by Application (2021–2032)
5.2.1 Global Polypeptide Vaccine Revenue by Application (2021–2026)
5.2.2 Global Polypeptide Vaccine Revenue by Application (2027–2032)
5.2.3 Global Polypeptide Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Polypeptide Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AmbioPharm
6.1.1 AmbioPharm Company Information
6.1.2 AmbioPharm Description and Business Overview
6.1.3 AmbioPharm Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AmbioPharm Polypeptide Vaccine Product Portfolio
6.1.5 AmbioPharm Recent Developments/Updates
6.2 Almac
6.2.1 Almac Company Information
6.2.2 Almac Description and Business Overview
6.2.3 Almac Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Almac Polypeptide Vaccine Product Portfolio
6.2.5 Almac Recent Developments/Updates
6.3 ACT
6.3.1 ACT Company Information
6.3.2 ACT Description and Business Overview
6.3.3 ACT Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 ACT Polypeptide Vaccine Product Portfolio
6.3.5 ACT Recent Developments/Updates
6.4 Ultimovacs
6.4.1 Ultimovacs Company Information
6.4.2 Ultimovacs Description and Business Overview
6.4.3 Ultimovacs Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Ultimovacs Polypeptide Vaccine Product Portfolio
6.4.5 Ultimovacs Recent Developments/Updates
6.5 Marker Therapeutics, Inc.
6.5.1 Marker Therapeutics, Inc. Company Information
6.5.2 Marker Therapeutics, Inc. Description and Business Overview
6.5.3 Marker Therapeutics, Inc. Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Marker Therapeutics, Inc. Polypeptide Vaccine Product Portfolio
6.5.5 Marker Therapeutics, Inc. Recent Developments/Updates
6.6 Immatics
6.6.1 Immatics Company Information
6.6.2 Immatics Description and Business Overview
6.6.3 Immatics Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Immatics Polypeptide Vaccine Product Portfolio
6.6.5 Immatics Recent Developments/Updates
6.7 OncoPep
6.7.1 OncoPep Company Information
6.7.2 OncoPep Description and Business Overview
6.7.3 OncoPep Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 OncoPep Polypeptide Vaccine Product Portfolio
6.7.5 OncoPep Recent Developments/Updates
6.8 Anergis
6.8.1 Anergis Company Information
6.8.2 Anergis Description and Business Overview
6.8.3 Anergis Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Anergis Polypeptide Vaccine Product Portfolio
6.8.5 Anergis Recent Developments/Updates
6.9 Sellas Life Sciences
6.9.1 Sellas Life Sciences Company Information
6.9.2 Sellas Life Sciences Description and Business Overview
6.9.3 Sellas Life Sciences Polypeptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sellas Life Sciences Polypeptide Vaccine Product Portfolio
6.9.5 Sellas Life Sciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Polypeptide Vaccine Industry Chain Analysis
7.2 Polypeptide Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Polypeptide Vaccine Production Mode & Process Analysis
7.4 Polypeptide Vaccine Sales and Marketing
7.4.1 Polypeptide Vaccine Sales Channels
7.4.2 Polypeptide Vaccine Distributors
7.5 Polypeptide Vaccine Customer Analysis
8 Polypeptide Vaccine Market Dynamics
8.1 Polypeptide Vaccine Industry Trends
8.2 Polypeptide Vaccine Market Drivers
8.3 Polypeptide Vaccine Market Challenges
8.4 Polypeptide Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Polypeptide Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Polypeptide Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Polypeptide Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Polypeptide Vaccine Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Polypeptide Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Polypeptide Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Polypeptide Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Polypeptide Vaccine Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Polypeptide Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Polypeptide Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Polypeptide Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Polypeptide Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Polypeptide Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Polypeptide Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Polypeptide Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Polypeptide Vaccine Sales by Region (K Dose), 2021–2026
Table 18. Global Polypeptide Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Polypeptide Vaccine Sales by Region (K Dose), 2027–2032
Table 20. Global Polypeptide Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Polypeptide Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Polypeptide Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Polypeptide Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Polypeptide Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Polypeptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Polypeptide Vaccine Sales by Country (K Dose), 2021–2026
Table 27. North America Polypeptide Vaccine Sales by Country (K Dose), 2027–2032
Table 28. North America Polypeptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Polypeptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Polypeptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Polypeptide Vaccine Sales by Country (K Dose), 2021–2026
Table 32. Europe Polypeptide Vaccine Sales by Country (K Dose), 2027–2032
Table 33. Europe Polypeptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Polypeptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Polypeptide Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Polypeptide Vaccine Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Polypeptide Vaccine Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Polypeptide Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Polypeptide Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Polypeptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Polypeptide Vaccine Sales by Country (K Dose), 2021–2026
Table 42. Latin America Polypeptide Vaccine Sales by Country (K Dose), 2027–2032
Table 43. Latin America Polypeptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Polypeptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Polypeptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Polypeptide Vaccine Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Polypeptide Vaccine Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Polypeptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Polypeptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Polypeptide Vaccine Sales (K Dose) by Type (2021–2026)
Table 51. Global Polypeptide Vaccine Sales (K Dose) by Type (2027–2032)
Table 52. Global Polypeptide Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Polypeptide Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Polypeptide Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Polypeptide Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Polypeptide Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Polypeptide Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Polypeptide Vaccine Price (US$/Dose) by Type (2021–2026)
Table 59. Global Polypeptide Vaccine Price (US$/Dose) by Type (2027–2032)
Table 60. Global Polypeptide Vaccine Sales (K Dose) by Application (2021–2026)
Table 61. Global Polypeptide Vaccine Sales (K Dose) by Application (2027–2032)
Table 62. Global Polypeptide Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Polypeptide Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Polypeptide Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Polypeptide Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Polypeptide Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Polypeptide Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Polypeptide Vaccine Price (US$/Dose) by Application (2021–2026)
Table 69. Global Polypeptide Vaccine Price (US$/Dose) by Application (2027–2032)
Table 70. AmbioPharm Company Information
Table 71. AmbioPharm Description and Business Overview
Table 72. AmbioPharm Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. AmbioPharm Polypeptide Vaccine Product
Table 74. AmbioPharm Recent Developments/Updates
Table 75. Almac Company Information
Table 76. Almac Description and Business Overview
Table 77. Almac Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Almac Polypeptide Vaccine Product
Table 79. Almac Recent Developments/Updates
Table 80. ACT Company Information
Table 81. ACT Description and Business Overview
Table 82. ACT Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. ACT Polypeptide Vaccine Product
Table 84. ACT Recent Developments/Updates
Table 85. Ultimovacs Company Information
Table 86. Ultimovacs Description and Business Overview
Table 87. Ultimovacs Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Ultimovacs Polypeptide Vaccine Product
Table 89. Ultimovacs Recent Developments/Updates
Table 90. Marker Therapeutics, Inc. Company Information
Table 91. Marker Therapeutics, Inc. Description and Business Overview
Table 92. Marker Therapeutics, Inc. Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Marker Therapeutics, Inc. Polypeptide Vaccine Product
Table 94. Marker Therapeutics, Inc. Recent Developments/Updates
Table 95. Immatics Company Information
Table 96. Immatics Description and Business Overview
Table 97. Immatics Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Immatics Polypeptide Vaccine Product
Table 99. Immatics Recent Developments/Updates
Table 100. OncoPep Company Information
Table 101. OncoPep Description and Business Overview
Table 102. OncoPep Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. OncoPep Polypeptide Vaccine Product
Table 104. OncoPep Recent Developments/Updates
Table 105. Anergis Company Information
Table 106. Anergis Description and Business Overview
Table 107. Anergis Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Anergis Polypeptide Vaccine Product
Table 109. Anergis Recent Developments/Updates
Table 110. Sellas Life Sciences Company Information
Table 111. Sellas Life Sciences Description and Business Overview
Table 112. Sellas Life Sciences Polypeptide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Sellas Life Sciences Polypeptide Vaccine Product
Table 114. Sellas Life Sciences Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Polypeptide Vaccine Distributors List
Table 118. Polypeptide Vaccine Customers List
Table 119. Polypeptide Vaccine Market Trends
Table 120. Polypeptide Vaccine Market Drivers
Table 121. Polypeptide Vaccine Market Challenges
Table 122. Polypeptide Vaccine Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report


List of Figures
Figure 1. Product Picture of Polypeptide Vaccine
Figure 2. Global Polypeptide Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Polypeptide Vaccine Market Share by Type: 2025 & 2032
Figure 4. Synthetic Polypeptide Vaccines Product Picture
Figure 5. Recombinant Polypeptide Vaccine Product Picture
Figure 6. Others Product Picture
Figure 7. Global Polypeptide Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Polypeptide Vaccine Market Share by Application: 2025 & 2032
Figure 9. Infectious Disease Prevention
Figure 10. Cancer Immunotherapy
Figure 11. Others
Figure 12. Global Polypeptide Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Polypeptide Vaccine Market Size (US$ Million), 2021–2032
Figure 14. Global Polypeptide Vaccine Sales (K Dose), 2021–2032
Figure 15. Global Polypeptide Vaccine Average Price (US$/Dose), 2021–2032
Figure 16. Polypeptide Vaccine Report Years Considered
Figure 17. Polypeptide Vaccine Sales Share by Manufacturers in 2025
Figure 18. Global Polypeptide Vaccine Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Polypeptide Vaccine Players: Market Share by Revenue in Polypeptide Vaccine in 2025
Figure 20. Polypeptide Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Polypeptide Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Polypeptide Vaccine Sales Market Share by Country (2021–2032)
Figure 23. North America Polypeptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 24. United States Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Polypeptide Vaccine Sales Market Share by Country (2021–2032)
Figure 27. Europe Polypeptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 28. Germany Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Polypeptide Vaccine Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Polypeptide Vaccine Revenue Market Share by Region (2021–2032)
Figure 35. China Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Polypeptide Vaccine Sales Market Share by Country (2021–2032)
Figure 43. Latin America Polypeptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Polypeptide Vaccine Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Polypeptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Polypeptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Polypeptide Vaccine by Type (2021–2032)
Figure 54. Global Revenue Market Share of Polypeptide Vaccine by Type (2021–2032)
Figure 55. Global Polypeptide Vaccine Price (US$/Dose) by Type (2021–2032)
Figure 56. Global Sales Market Share of Polypeptide Vaccine by Application (2021–2032)
Figure 57. Global Revenue Market Share of Polypeptide Vaccine by Application (2021–2032)
Figure 58. Global Polypeptide Vaccine Price (US$/Dose) by Application (2021–2032)
Figure 59. Polypeptide Vaccine Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies